Clinical trial
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
NCT00002095 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- 700
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.